Form 4: Tyra Biosciences Director Acquires Stock Options

Tyra Biosciences Director Adele M. Gulfo acquired stock options under the company's Non-Employee Director Compensation Program.

Summary

• Adele M. Gulfo, a Director at Tyra Biosciences, Inc., was granted stock options on May 28, 2026.
• The options grant the right to buy 13,160 shares of common stock at an exercise price of $32.68 per share.
• The options vest monthly over a period of 12 months following the grant date, with full vesting by May 27, 2036.
• Vesting is contingent upon continuous service to the Issuer through each vesting date.
• In certain circumstances, unvested options may vest on the date of the next annual stockholder meeting if it occurs before the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation rather than significant financial performance or strategic shifts.

Positives

• Director compensation aligns with shareholder interests through stock options.
• The grant of options indicates continued confidence in the company's future prospects by a key insider.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The exercise price of $32.68 suggests the options are currently out-of-the-money if the stock price is below this level.
• The filing does not provide current stock price information for context.

Risks

• The value of the stock options is directly tied to the future performance of Tyra Biosciences' stock price.
• If the company's stock price does not appreciate significantly, the options may not provide material financial benefit to the director.
• The vesting is subject to the director's continuous service, implying a risk of forfeiture if service is terminated.

Future Outlook

The vesting schedule and grant of stock options suggest a positive outlook for the company's stock performance, as the director's compensation is tied to it.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation. This type of compensation is standard for incentivizing leadership in companies with potentially high growth but also significant inherent risks.

Corporate Governance

Related Party Transactions

• The transaction involves a grant of stock options to a Director (Adele M. Gulfo) under the company's Non-Employee Director Compensation Program, which is a standard related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with stock performance, potentially benefiting shareholders if the stock price increases. However, it also represents potential dilution if options are exercised.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers/Customers: No direct impact mentioned.

Next Steps

• The director will continue to serve the Issuer, with options vesting monthly.
• The director's beneficial ownership will increase as options vest and potentially are exercised.

Key Dates

Keywords

Tyra Biosciences, Form 4, Stock Options, Insider Trading, Director Compensation, SEC Filing, TYRA, Beneficial Ownership